Abstract A randomized, multicenter, open-label, phase 3 study of patients with progressive, recurrent glioblastoma multiforme (GBM) for whom front-line therapy had failed was conducted. This study was designed to determine whether combination therapy with imatinib and hydroxyurea (HU) has superior antitumor activity compared with HU monotherapy in the treatment of recurrent GBM. The target population consisted of patients with confirmed recurrent GBM and an Eastern Cooperative Oncology Group performance status of 0-2 who had completed previous treatment comprising surgical resection, irradiation therapy, and first-line chemotherapy (preferably temozolomide (TMZ) containing regimen) and who have progressed despite treatment. If first-line chemotherapy did not contain TMZ, a second completed chemotherapy was acceptable. The primary efficacy parameter was progression-free survival (PFS). The primary comparison of combination therapy versus monotherapy for PFS was not significant (adjusted P = 0.56). The hazard ratio (HR) (adjusted HR = 0.93) was not clinically relevant.
Introduction
Glioblastoma multiforme (GBM) (World Health Organization grade IV) is a high-grade malignancy of the central nervous system with poor prognosis. The rate of progression-free survival (PFS) at 1 year is approximately 40% [1] . To date, surgery, followed by irradiation and concomitant temozolomide (TMZ) is considered a standard of care for newly diagnosed GBM. Alternative treatment for newly diagnosed GBM is the implantation at surgery of wafers delivering 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) into the resection cavity, in combination with irradiation. Although PFS can be prolonged by approximately 3-6 months, median overall survival (OS) remains unsatisfactory at 16 months, and recurrence rates are high [1] .
Treatment at disease progression includes resection, if possible, and/or further chemotherapy or radiotherapy; however, outcomes remain poor. Many new approaches have been tested in the recurrent setting, including novel chemotherapy agents, chemotherapy combinations, and, more recently, agents targeting epidermal growth factor receptor (EGFR), platelet-derived growth factor receptors (PDGFR), and vascular endothelial growth factor receptor [2] . In GBM, EGFR and PDGFR are amplified in approximately 50 [2] and 21% of patients, respectively [3] . Recently, the monoclonal antibody bevacizumab has also shown promise in recurrent GBM, in combination with cytotoxic chemotherapy such as irinotecan [4] .
Imatinib has limited single-agent antitumor activity in patients with progressive recurrent GBM [5, 6] . Imatinib is known to inhibit the signaling pathways of PDGFRa, PDGFRb, and c-KIT receptors. Hydroxyurea (HU) is thought to promote the penetration of drugs across the blood-brain barrier, as well as to induce the loss of amplified genes, including the EGFR gene [7] . Because PDGFR, c-KIT, and EGFR overexpression is seen in GBM [8] and HU can increase permeability of the blood-brain barrier, combining the drugs was considered a treatment option worth investigating. Results of a pilot study of 30 patients with recurrent GBM demonstrated that a combination of HU and imatinib is efficacious and well tolerated for the treatment of recurrent GBM [9] [10] [11] . The findings were subsequently confirmed by phase 2 studies conducted by an independent group [12, 13] .
Patients and methods
The present study was a multicenter, 2-arm, open-label, phase 3 study for patients with recurrent GBM. The primary objective was to evaluate whether a combination of imatinib and HU was superior to HU alone in prolonging PFS. Secondary objectives included PFS at 12 months, overall response, duration of response, safety, and OS.
Adult patients with a histologically confirmed GBM, measurable disease, and an Eastern Cooperative Oncology Group (ECOG) performance score B2 who had previously undergone surgery and received radiotherapy and prior chemotherapy were eligible for randomization. Patients on steroids were required to have been on a stable dose for C5 days. Patients at excessive risk of intracranial hemorrhagic events (evidence of intracranial hemorrhage in initial magnetic resonance imaging (MRI) scan or in MRI at less than 4 weeks after surgery) or with evidence of intratumoral hemorrhage at baseline scan, were not eligible. Patients were required to have adequate renal, hepatic, and hematologic function.
Following previous research [13, 14] , patients were stratified according to their use of enzyme-inducing antiepileptic drugs (EIAEDs) or not; however, the dose of imatinib was not altered per stratification. The choice of 1,000 mg/d of HU was based on reported efficacy of the single agent in patients with recurrent or unresectable meningioma [14] .
The study included 240 patients randomized to receive 1,500 mg/d of HU (500 mg three times daily) or imatinib 600 mg/d in combination with 1,000 mg/d of HU (500 mg twice daily) (Fig. 1) . The difference in HU dose between the treatment arms is a result of the suggestion that imatinib may enhance HU cytotoxicity [13] . Following randomization, patients received treatment until progression or trial withdrawal. The protocol scheduled an evaluation using the Macdonald et al. criteria [15] to be performed every 6 weeks from treatment start. Upon progression, patients with good performance status who were receiving HU alone were permitted to switch to the combination arm. For patients progressing on the combination arm, the dose of imatinib could be escalated to 800 mg/d while the dose of HU remained unchanged. Dose escalation in the combination arm is justified by results from a previous study in which some patients benefited from a dose increase from 600 mg/d to 800 mg/d of imatinib [16] .
In the event of further progression, patients receiving imatinib 800 mg/d were withdrawn from the trial. Only the first progression on treatment was evaluated for the primary end point.
All MRI scans and neurologic and steroid information were evaluated at the local (investigator) study sites in addition to a review by a blinded central independent reviewer (CIR) (Dr Greg Sorensen, Massachusetts General Hospital, Boston, USA), applying the Macdonald et al. criteria for tumor response [15] . Blinded CIR data were used for the primary analyses on an intent to treat (ITT) basis, and sensitivity analyses were performed to compare the CIR results with the results documented at the sites.
GBM is a highly aggressive malignancy which progress very rapidly. Therefore, we defined stabilization of the disease for at least 2 months as response, as it indicates an improvement compared with the unaffected course of the disease. The definition and the role of stable disease as a treatment effect in GBM are controversial and should be clarified in further studies.
Statistical analyses
Median PFS was expected to be 16 and 10 weeks for the combination and monotherapy groups, respectively. Based on a 90% power to exceed stopping boundaries defined for the interim analysis, an estimated 204 events (progression, death) were needed. Therefore, 240 patients needed to recruited to allow for premature withdrawals.
Hazard ratios (HR) and the associated P values were derived from a Cox proportional hazards model stratified for EIAED use (yes, no) and ECOG status (\2, C2). The HR indicates the effect of combination therapy or monotherapy, and HR \ 1 favors combination therapy.
Results
Between October 2004 and July 2006, 240 patients from 19 institutions in four countries were randomized to receive HU alone (n = 120) or HU plus imatinib (n = 120). The characteristics of the patients were balanced between the two arms at baseline (Table 1) . Overall, the median age was 51 years, more women were in the combination arm, and 23% of patients were ECOG performance status 2 ( Table 2 ). The median time from initial diagnosis was 12 months in both arms. No significant differences existed between the 2 arms regarding age, performance status, time from initial diagnosis, use of EIAEDs, and prior anti-cancer therapy. Approximately 40% of patients had received multiple chemotherapy regimens before study entry, and some had undergone multiple resections.
Patients (N = 240) were randomized in a 1:1 ratio, with 118 patients on each arm starting treatment (Table 3) . At the time of data cutoff for the analysis (October 27, 2006), seven patients on combination therapy (6%) and 14 (12%) on HU monotherapy were still on treatment. Most discontinuations were a result of disease progression and were diagnosed by objective identification using follow-up MRI scan or were suspected on clinical grounds (e.g, deteriorating neurologic state or performance status). Adverse events (AEs) were responsible for discontinuation of study medication in 18 patients (15%) on combination therapy and 20 patients (17%) on monotherapy.
Primary efficacy results
No significant differences in PFS rates were found between combination therapy and monotherapy following CIR analysis (adjusted P = 0.56) ( Table 4 ; Fig. 2 ). The HR of 0.93 (95% CI, 0.71-1.2) favored combination therapy but was not clinically meaningful. The median PFS for the two treatment arms was six and 6 weeks for the combination and monotherapy arms, respectively. The 6-month PFS rates were 5 and 7%, respectively.
Of note is the high number of patients who were given an assessment of progressive disease (PD) based on neurologic assessment or steroid use alone. Given time, these patients probably would have been assessed with PD by MRI, but their early censoring in this manner would have adversely affected the PFS calculations.
Secondary efficacy results Figure 3 shows the OS of the ITT population, but does not include patients who progressed while on monotherapy before switching to the combination arm or patients randomized to combination therapy who were then treated with a higher dose of imatinib.
The HR for OS (0.92) was similar to that observed for the primary PFS analysis (0.93). There were no significant differences between the combination therapy and monotherapy arms. The median time to death for the combination arm was 21 weeks and is similar to the median time to death in the monotherapy arm (19 weeks). The 6-month OS rates in the two treatment groups also were similar: 40% in the combination arm and 37% in the monotherapy arm.
CIR data showed two confirmed responders in the combination therapy arm and one in the monotherapy arm. The percentage of patients with a best overall response of stable disease (SD) or better (complete response plus partial response plus SD) was similar for each treatment group at approximately 25%. PD or death was estimated for 68% of patients, and 7% were not assessable. There were no significant differences between treatment groups.
Safety evaluation
Disease progression was the most frequent cause of death during the study and accounted for 90 and 85% of deaths in the combination and monotherapy arms, respectively (Table 5 ). Other causes of death included pneumonia, pulmonary embolism, and sepsis, all of which were not unexpected for patients with recurrent GBM.
The rates of AEs leading to discontinuation were similar in both treatment groups (16% vs. 18% in the monotherapy and combination therapy groups, respectively). The only AEs leading to discontinuation that occurred in more than 2% of patients were general physical health deterioration (3%, combination therapy arm; 5%, monotherapy arm) and pneumonia (2%, combination therapy arm). Most AEs that led to discontinuation were considered a consequence of disease progression. Table 6 reports grade 3 and 4 AEs that occurred in more than 5% of patients in any group. Both treatment arms reported similar AEs, and no difference was seen in the combination arm when reviewing patients before and after crossover. Headache, fatigue, nausea, peripheral edema, and thrombocytopenia were the most frequently observed AEs. Most were associated with the disease, and their incidence was as expected. The serious AEs observed were expected for this indication and class of study drug. There were no clinically relevant intracerebral hemorrhages observed, and no discontinuation of study medication occurred due to intracerebral hemorrhage in either arm. When the trial data were compared with previous experience with imatinib single agent studies, no new safety concerns were identified.
Sensitivity analyses
Originally, the CIR was not included in the study design and setup. Following CIR endorsement, differences between central review and the local site review could be seen. Several preplanned sensitivity analyses were included, such as the impact of including and excluding steroid and neurologic data on the response determination; the timing of recruitment to the study (later amendments had increasingly strict criteria on inclusion); censoring according to the previous assessment (as opposed to time of data cutoff); the impact of results from recruiting sites that recruited significantly more patients (approximately 60 patients, compared to 15-20 patients at other sites) on the overall results; and whether PD was reported at the time of crossover or imatinib dose increase. Of the eight preplanned sensitivity analyses on PFS, seven showed no statistically significant difference between the two treatment groups. The exception was an analysis that may have been influenced by subjective judgments (valid inclusion of ''soft symptoms'' such as improved symptom control and quality of life) during the investigator review, at those sites that showed a significant improvement for patients in the combination therapy arm (median PFS, 9 weeks; 6-month PFS, 12%; P = 0.0040). 
Treatment status
Randomized to study treatment 120 (100) 120 (100) 240 (100)
Not exposed to study treatment 2 (2) 2 (2) 4 (2) Discontinued study treatment (15) 20 (17) 38 ( 
Discussion
This study shows no statistically significant differences between the two arms with respect to the primary and secondary end points, indicating that combination therapy with imatinib and HU was not superior to HU monotherapy in the current GBM setting. Sensitivity analyses highlighted a difference in interpretation between investigator Patients alive and without progression were considered to be censored at the time of last available visit assessment PFS time percentiles and rates were calculated using the Kaplan-Meier method, ignoring strata HR and the associated P value were derived from a Cox proportional hazards model stratified for EIAED use (yes, no) and ECOG status (\2, C2). The hazard ratio indicates the effect of combination therapy and monotherapy. An HR \ 1 favors combination therapy and CIR assessments, but this could not be attributed to a single influencing factor. No new safety concerns were identified for either treatment group.
In the current study, several potential confounding factors may have resulted in an underestimation of efficacy. Use of EIAEDs in nearly half of the patients in the (9) 10 (12) All AEs starting after first dose but not later than 28 days after last dose were analyzed. AEs were assigned to the treatment group of the patient at the time of onset of the AE combination therapy arm may have resulted in suboptimal dosing of imatinib [17] , as imatinib dosing was not adjusted to compensate for concomitant EIAEDs use. Progressing GBM is usually accompanied by substantial brain edema. Imatinib may increase the likelihood of edema while simultaneously inhibiting tumor growth [13] . Adjusting the steroid dose is used to reduce brain edema, regardless of the etiology of the edema. In the current trial, any increase in steroid dose automatically led to the classification of PD, regardless of when it happened. The tumor evaluation criteria did not optimally reflect the previously described practice among neuro-oncologists, resulting in a discrepancy between investigator and CIR results: namely, patients were classified with PD by CIR when they were assessed as SD locally. Many patients with PD were defined as relapsing by either neurologic worsening or steroid increase, and many of these were defined early during patients' treatment (i.e, within the first 6 weeks). Patients' continuation on the study was determined locally by investigators, not according to CIR, which was obtained primarily retrospectively. Subsequently, many patients classified as PD by CIR continued to receive medication after the first 6 weeks of treatment because they were classified locally as SD. It is therefore suggested that the evaluation criteria for GBM should be reviewed in a scientific consensus conference so as to avoid such evaluation discrepancies in future trials.
The differences between CIR and investigator responses were consistent across sites, so although investigator bias cannot be fully excluded, it could hardly be the sole reason for the difference. The nature of the GBM progression would mean that any drug, whether cytotoxic or cytostatic (particularly the latter), would take time to slow the advancement of the disease and even more time to start reversing its course. The investigator responses suggest an apparent time delay between the start of treatment and stabilization of tumor proliferation.
Alternative evaluation of the disease during the first 2-3 months would not account for all disease progressions, but would allow time for stabilization to be achieved, both symptomatically and neurologically. By adjusting the steroid dose as required within the first few months, without any dose increase, which would result in a tumor assessment of PD, brain edema could be adequately controlled. This in turn would permit assessment of the study drug's performance in stabilizing or reducing tumor burden, as well as its impact on control of edema.
Conclusion
According to the strict Macdonald et al. criteria [15] , no clinically meaningful differences were found in median PFS between the two treatment arms. OS and PFS at 6 and 12 months were generally similar to benchmarks for the treatment outcomes of patients treated for recurrent progressing GBM. No safety issues arose for patients receiving imatinib that were either previously unknown or not expected as a consequence of the disease. A distinct difference between CIR and investigator evaluations was observed. A discrepancy between central MRI evaluation and investigator responses during the course of the trial was apparent, suggesting differences in the application of the Macdonald et al. criteria.
In summary, this study indicates that there is no clinically meaningful benefit of imatinib and HU combination therapy compared to HU alone in progressive, TMZrefractory GBM; therefore, the use of this combination should be discouraged for GBM patients at first relapse.
